PDS Biotechnology
PDSB
43 hedge funds and large institutions have $11M invested in PDS Biotechnology in 2018 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 11 increasing their positions, 15 reducing their positions, and 29 closing their positions.
0.04% more ownership
Funds ownership: 1.68% → 1.71% (+0.04%)
10% less capital invested
Capital invested by funds: $12.2M → $11M (-$1.2M)
27% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 15
28% less funds holding
Funds holding: 60 → 43 (-17)
59% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 29
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
+$857K |
| 2 |
GTC
Ghost Tree Capital
New York
|
+$783K |
| 3 |
Millennium Management
New York
|
+$513K |
| 4 |
Two Sigma Investments
New York
|
+$245K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
+$244K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$877K |
| 2 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$420K |
| 3 |
State Street
Boston,
Massachusetts
|
-$346K |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$337K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$179K |
PDSB Hedge Fund Activity: Q2 2018 in Review
43 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in PDS Biotechnology (PDSB) for Q2 2018, worth a combined $11M — down 9.8% from $12.2M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of PDSB and 12 opened new positions — a net loss of 17 holders — while 15 trimmed existing stakes and 11 added.
The largest buyer was D.E. Shaw & Co, adding an estimated $857K. The largest seller was BlackRock, cutting an estimated $877K.
- 43 institutional investors held PDS Biotechnology (PDSB) as of Q2 2018, down from 60 in Q1 2018.
- Funds reported $11M of PDS Biotechnology stock for Q2 2018, down 9.8% quarter-over-quarter.
- 12 funds opened new PDS Biotechnology positions in Q2 2018 and 29 closed out, a net change of -17 holders.
- The largest PDS Biotechnology buyer in Q2 2018 was D.E. Shaw & Co, an estimated $857K added.
- The largest PDS Biotechnology seller in Q2 2018 was BlackRock, an estimated $877K sold.
Based on aggregated 13F filings for Q2 2018.